Cantor Fitzgerald Maintains Overweight on Vertex Pharmaceuticals, Raises Price Target to $229

Cantor Fitzgerald maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Overweight and raises the price target from $217 to $229.

Benzinga · 11/19/2019 15:54

Cantor Fitzgerald maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Overweight and raises the price target from $217 to $229.